Wave Life Sciences Ltd. (NASDAQ:WVE) Expected to Earn Q3 2025 Earnings of ($0.36) Per Share

Wave Life Sciences Ltd. (NASDAQ:WVE) – Equities research analysts at Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for shares of Wave Life Sciences in a report issued on Tuesday, September 24th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.36) per share for the quarter, up from their previous estimate of ($0.38). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.04) per share. Leerink Partnrs also issued estimates for Wave Life Sciences’ Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.43) EPS and FY2026 earnings at ($0.93) EPS.

WVE has been the subject of a number of other reports. Mizuho restated an “outperform” rating and issued a $19.00 target price on shares of Wave Life Sciences in a research note on Tuesday, June 25th. HC Wainwright upped their target price on Wave Life Sciences from $15.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday. B. Riley assumed coverage on Wave Life Sciences in a research note on Thursday, September 19th. They issued a “buy” rating and a $11.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on Wave Life Sciences in a research note on Friday. They issued an “overweight” rating and a $13.00 target price for the company. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Wave Life Sciences currently has an average rating of “Moderate Buy” and an average target price of $13.75.

Wave Life Sciences Stock Up 3.4 %

Shares of WVE stock opened at $8.29 on Friday. Wave Life Sciences has a 12 month low of $3.50 and a 12 month high of $9.92. The firm has a market cap of $1.02 billion, a PE ratio of -15.94 and a beta of -1.13. The stock has a 50 day moving average of $6.03 and a 200-day moving average of $5.85.

Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.09). Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. The company had revenue of $19.69 million during the quarter, compared to analyst estimates of $24.80 million. During the same quarter last year, the firm posted ($0.20) earnings per share.

Insider Activity

In other news, CEO Paul Bolno sold 48,366 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $5.78, for a total transaction of $279,555.48. Following the transaction, the chief executive officer now owns 359,059 shares of the company’s stock, valued at $2,075,361.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Paul Bolno sold 48,366 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $5.78, for a total transaction of $279,555.48. Following the transaction, the chief executive officer now owns 359,059 shares of the company’s stock, valued at $2,075,361.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kyle Moran sold 17,146 shares of the company’s stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total value of $154,314.00. Following the transaction, the chief financial officer now directly owns 19,777 shares in the company, valued at approximately $177,993. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Wave Life Sciences

Several hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank acquired a new stake in shares of Wave Life Sciences during the fourth quarter worth about $770,000. Teacher Retirement System of Texas acquired a new stake in shares of Wave Life Sciences during the fourth quarter worth about $86,000. Trexquant Investment LP acquired a new stake in shares of Wave Life Sciences during the fourth quarter worth about $162,000. TD Asset Management Inc raised its position in shares of Wave Life Sciences by 26.5% during the fourth quarter. TD Asset Management Inc now owns 205,746 shares of the company’s stock worth $1,039,000 after purchasing an additional 43,054 shares during the period. Finally, Capstone Investment Advisors LLC acquired a new stake in shares of Wave Life Sciences during the fourth quarter worth about $252,000. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.